Practice Variations in the Use of Novel Oral Anticoagulants for Nonvalvular Atrial Fibrillation-Related Stroke among Stroke Neurologists in Saudi Arabia.

ABSTRACT: Clinical trials have demonstrated that novel oral anticoagulants (NOACs) are noninferior to warfarin in preventing nonvalvular atrial fibrillation- (nvAF-) related stroke and systemic embolism. However, in these trials, NOACs initiation was delayed for a variable period after stroke. Herein, we aimed to investigate the variability in early initiation of NOACs after nvAF-related stroke among stroke neurologists in Saudi Arabia. A standardized questionnaire was distributed electronically to all the stroke neurologists and fellows in Saudi Arabia. The questionnaire primarily focused on the timing of NOACs initiation after an nvAF-related stroke, according to stroke size (small, medium, and large) and location (anterior or posterior circulation). Thirty-six (85.7%) of the 42 stroke neurologist

SUBMITTER: Alanazy MH 

PROVIDER: S-EPMC6721244 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature